The risk-of-malignancy index to evaluate potential ovarian cancers in local hospitals
- PMID: 10074998
The risk-of-malignancy index to evaluate potential ovarian cancers in local hospitals
Abstract
Objective: To assess the risk-of-malignancy index (a scoring system based on menopausal status, ultrasound features, and serum CA 125) at district hospitals for referral of women with suspected malignant pelvic masses for primary surgery at a central gynecologic oncology unit.
Methods: All seven hospitals in Health Region IV, Norway, agreed to refer women with pelvic masses and risk-of-malignancy indices of 200 or more for centralized primary surgery. In total, 365 women 30 years of age or older, admitted consecutively at the local hospitals, were enrolled in the study from February 1, 1995, to January 31, 1997.
Results: Compliance with the study was satisfactory; 84% (65 of 77) of women with risk-of-malignancy indices of at least 200 were referred for centralized primary surgery. Sensitivity and specificity to malignancy were 71% and 92%, respectively, which is in agreement with previous validation of the risk-of-malignancy index in teaching hospital settings. False negatives were due mainly to stage Ia (18 of 24) ovarian cancer, whereas 27 of 28 stage II-IV ovarian cancer cases were identified correctly.
Conclusion: The risk-of-malignancy index identified women with malignant pelvic masses efficiently. Our study showed the risk-of-malignancy index strategy in a practical setting to be able to centralize primary surgery for advanced ovarian cancer from local hospitals to a subspecialty unit. We recommend the risk-of-malignancy index for detection of patients with advanced ovarian cancer for centralized primary surgery.
Similar articles
-
The accurate staging of ovarian cancer using 3T magnetic resonance imaging--a realistic option.BJOG. 2008 Jun;115(7):894-901. doi: 10.1111/j.1471-0528.2008.01716.x. BJOG. 2008. PMID: 18485169
-
Validation of referral guidelines for women with pelvic masses.Obstet Gynecol. 2005 Jan;105(1):35-41. doi: 10.1097/01.AOG.0000149159.69560.ef. Obstet Gynecol. 2005. PMID: 15625139
-
Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.Oncologist. 1996;1(5):326-330. Oncologist. 1996. PMID: 10388011
-
Ovarian malignancy in breast cancer patients with an adnexal mass.Obstet Gynecol. 2005 Mar;105(3):507-13. doi: 10.1097/01.AOG.0000154162.51442.14. Obstet Gynecol. 2005. PMID: 15738016 Review.
-
Managing ovarian masses during pregnancy.Obstet Gynecol Surv. 2006 Jul;61(7):463-70. doi: 10.1097/01.ogx.0000224614.51356.b7. Obstet Gynecol Surv. 2006. PMID: 16787549 Review.
Cited by
-
Biomarkers in Ovarian Pathology: From Screening to Diagnosis. Review of the Literature.J Pers Med. 2021 Oct 29;11(11):1115. doi: 10.3390/jpm11111115. J Pers Med. 2021. PMID: 34834467 Free PMC article. Review.
-
Multianalyte assay systems in the differential diagnosis of ovarian cancer.Expert Opin Med Diagn. 2012 Mar;6(2):131-138. doi: 10.1517/17530059.2012.661711. Expert Opin Med Diagn. 2012. PMID: 22468148 Free PMC article.
-
The Diagnosis, Treatment, Prognosis and Molecular Pathology of Borderline Ovarian Tumors: Current Status and Perspectives.Cancer Manag Res. 2020 May 19;12:3651-3659. doi: 10.2147/CMAR.S250394. eCollection 2020. Cancer Manag Res. 2020. PMID: 32547202 Free PMC article. Review.
-
Risk of Malignancy Index (RMI) in Evaluation of Adnexal Mass.J Obstet Gynaecol India. 2015 Apr;65(2):117-21. doi: 10.1007/s13224-014-0609-1. Epub 2014 Oct 7. J Obstet Gynaecol India. 2015. PMID: 25883443 Free PMC article.
-
Morphological parameters of ovarian masses and accuracy of the risk of malignancy index in diagnosing ovarian malignancy.Prz Menopauzalny. 2022 Jun;21(2):81-91. doi: 10.5114/pm.2022.116402. Epub 2022 May 24. Prz Menopauzalny. 2022. PMID: 36199743 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials